NAII

Business Context and Reporting Period

Company: Natural Alternatives International, Inc. (NAI)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2010
Business Overview: NAI operates primarily in private label contract manufacturing for nutritional supplements and health care products, with a smaller branded products segment (Pathway to Healing). The company has divested its legacy Real Health Laboratories (RHL) business, which is now reported as discontinued operations.

Key Financial Metrics

Note: All figures in thousands except per share data and percentages.

Material Changes vs. Prior Period

• Revenue: Net sales for the nine months ended March 31, 2010, decreased 6.1% to $51.2 million compared to $54.5 million in the prior year. Private label contract manufacturing sales declined 5.6%, while branded products sales dropped 17.1%.
• Profitability: Operating income from continuing operations improved significantly, turning from a loss of $0.9 million in the prior year nine-month period to a profit of $3.0 million. This was driven by cost reduction programs and improved gross margins.
• Net Income: Net income swung from a loss of $5.2 million in the prior year to a profit of $3.9 million. This reversal is largely attributable to a significant tax benefit of approximately $3.2 million resulting from the write-off of the tax basis in the sold RHL stock.
• Liquidity: Cash and cash equivalents increased from $4.0 million at June 30, 2009, to $7.8 million at March 31, 2010. Operating cash flow improved to $5.3 million for the nine-month period.
• Debt: Total debt decreased to $496,000, consisting entirely of a term loan. The working capital line of credit balance remained at zero.

Guidance, Outlook, and Risks

• Outlook: Management expects net sales and operating income for the fourth quarter of fiscal 2010 to be lower than the comparable prior year period due to uncertain economic conditions and anticipated reduced sales volumes/pricing from largest customers.
• Strategic Initiatives: Plans include increasing marketing efforts for the "Pathway to Healing" line, re-launching Dr. Cherry products with new formulations, and leveraging certified facilities to attract new contract manufacturing customers.
• Customer Concentration: Revenue concentration risk remains high. The two largest customers accounted for 83% of total net sales for the nine months ended March 31, 2010 (up from 79% in the prior year).
• Foreign Exchange: Results are sensitive to fluctuations in the Swiss Franc and Euro against the U.S. dollar, which impacted foreign exchange losses in the period.
• Discontinued Operations: The legacy RHL business has been sold. A potential earn-out of up to $500,000 was eliminated in February 2010 due to the buyer's operational results.

Investor Verification Checklist

• Tax Benefit Sustainability: Verify the one-time nature of the $3.2 million tax benefit from the RHL stock write-off and its impact on the reported net income.
• Customer Dependency: Assess the risk associated with the top two customers representing 83% of revenue and the specific sales trends for Mannatech and NSA International.
• Branded Product Decline: Review the long-term viability of the "Pathway to Healing" brand following the cessation of the Dr. Cherry television program and the 17% sales decline.
• Foreign Currency Exposure: Monitor the impact of Euro and Swiss Franc fluctuations on the European subsidiary (NAIE), which generated approximately 69% of non-U.S. sales.
• Cost Reduction Durability: Confirm that the $2.5 million in operating overhead savings realized in the first nine months of fiscal 2010 is sustainable.